Orlistat treatment is safe in overweight and obese liver transplant recipients: A prospective, open label trial

Transplant International

Volumn 19, Issue 12, 2006, Pages 1000-1005

  Cassiman, David ^a   Roelants, Mieke ^a   Vandenplas, Gerda ^a   Van Der Merwe, Schalk W ^b   Mertens, Ann ^a   Libbrecht, Louis ^a   Verslype, Chris ^a   Fevery, Johan ^a   Aerts, Raymond ^a   Pirenne, Jacques ^a   Muls, Erik ^a   Nevens, Frederik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cyclosporin; Drug interaction; Nonalcoholic fatty liver disease; Tacrolimus; Weight loss

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TETRAHYDROLIPSTATIN;

ABDOMINAL DISEASE; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; GRAFT RECIPIENT; HUMAN; HYPERVENTILATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; MUSCULOSKELETAL DISEASE; NUTRITIONAL ASSESSMENT; OBESITY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEATORRHEA; SUBARACHNOID HEMORRHAGE; TREATMENT DURATION; WAIST CIRCUMFERENCE;

ADULT; AGED; ANTI-OBESITY AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; LACTONES; LIPIDS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PILOT PROJECTS; PROSPECTIVE STUDIES; TACROLIMUS;

EID: 33750580407     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00379.x     Document Type: Article

References (26)

1. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461.
2. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998; 4: 285.
3. Munoz SJ, Elgenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005; 11: S52.
4. la Fleur SE, Ji H, Manalo SL, Friedman MI, Dallman MF. The hepatic vagus mediates fat-induced inhibition of diabetic hyperphagia. Diabetes 2003; 52: 2321.
5. la Fleur SE, Manalo SL, Roy M, Houshyar H, Dallman MF. Hepatic vagotomy alters limbic and hypothalamic neuropeptide responses to insulin-dependent diabetes and voluntary lard ingestion. Eur J Neurosci 2005; 21: 2733.
6. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21(Suppl. 3):S12.
7. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125.
8. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167.
9. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235.
10. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713.
11. Zhi J, Moore R, Kanitra L, Mulligan TE. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002; 42: 1011.
12. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63: 367.
13. Cailotto C, La Fleur SE, Van Heijningen C, et al. The suprachiasmatic nucleus controls the daily variation of plasma glucose via the autonomic output to the liver: are the clock genes involved? Eur J Neurosci 2005; 22: 2531.
14. Colman E, Fossler M. Reduction in blood cyclosporine concentrations by orlistat. N Engl J Med 2000; 342: 1141.
15. Errasti P, Garcia I, Lavilla J, Ballester B, Manrique J, Purroy A. Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. Transplant Proc 2002; 34: 137.
16. Evans S, Michael R, Wells H, et al. Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat. Am J Kidney Dis 2003; 41: 493.
17. Le Beller C, Bezie Y, Chabatte C, Guillemain R, Amrein C, Billaud EM. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000; 70: 1541.
18. Nagele H, Petersen B, Bonacker U, Rodiger W. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. Eur J Clin Pharmacol 1999; 55: 667.
19. Schnetzler B, Kondo-Oestreicher M, Vala D, Khatchatourian G, Faidutti B. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. Transplantation 2000; 70: 1540.
20. Kim DH, Lee EH, Hwang JC, et al. [A case of acute cholestatic hepatitis associated with Orlistat]. Taehan Kan Hakhoe Chi 2002; 8: 317.
21. Lau G, Chan CL. Massive hepatocellular (correction of hepatocullular) necrosis: was it caused by Orlistat? Med Sci Law 2002; 42: 309.
22. Montero JL, Muntane J, Fraga E, et al. Orlistat associated subacute hepatic failure. J Hepatol 2001; 34: 173.
23. Thurairajah PH, Syn WK, Neil DA, Stell D, Haydon G. Orlistat (Xenical)-induced subacute liver failure. Eur J Gastroenterol Hepatol 2005; 17: 1437.
24. Chounta A, Tsiodras S, Zouridakis S, Doumas M, Giamarellou H. Sibutramine use associated with reversible hepatotoxicity. Ann Intern Med 2005; 143: 763.
25. Blackburn GL, Mun EC. Effects of weight loss surgeries on liver disease. Semin Liver Dis 2004; 24: 371.
26. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005; 5: 1383.